{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-106591","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.825010+00:00","generated_at":"2026-05-17T00:17:22.626921+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palvella announces QTORIN pitavastatin for DSAP; Phase 2 trial planned H2 2026","bullets":["New candidate targets DSAP, a rare genetic skin disease with no FDA-approved therapies.","DSAP affects an estimated >50,000 diagnosed U.S. patients and is premalignant.","Company plans to meet FDA in H1 2026; Phase 2 trial initiation expected H2 2026.","QTORIN pitavastatin designed to inhibit the mevalonate pathway, the causal driver of DSAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-106591","json":"https://secwatch.observer/filing/0001104659-25-106591.json","markdown":"https://secwatch.observer/filing/0001104659-25-106591.md","text":"https://secwatch.observer/filing/0001104659-25-106591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/0001104659-25-106591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/tm2530285d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:17:22.626921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}